Search
Showing results for "lung disease preterm"
The results of the Kwinana Children's Health Respiratory Study have today been sent to the nearly 600 participating children from almost 500 families
Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
We investigated the suggestion that otitis-prone children have an impaired antibody response in the context of pneumococcal vaccination.
World-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.
Clinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.
Dysfunction of T follicular-helper cells is a possible cause of impaired germinal centre and IgG antibody responses in individuals with HIV
Conserved vaccine candidate proteins from S.pneumoniae induce serum and salivary antibody responses in Aboriginal and non-Aboriginal children with history of OM
Coming up in 2021 We have a a study to suit every age range in 2021! From babies at just six weeks for the FluBub Study, through to teenagers in
Christopher Elke Jennifer Tom Blyth Seppanen Kent Snelling MBBS (Hons) DCH FRACP FRCPA PhD BSc PhD RN BMBS DTMH GDipClinEpid PhD FRACP Centre Head,
This article explores how to support a child's physical and mental health during critical developmental periods, known as the first 1,000 days of life.